- Home
- MYGN vs EWTX Comparison
MYGN vs EWTX Comparison
Compare MYGN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- EWTX
- Stock Information
- Founded
- MYGN 1991
- EWTX 2017
- Country
- MYGN United States
- EWTX United States
- Employees
- MYGN N/A
- EWTX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- EWTX Health Care
- Exchange
- MYGN Nasdaq
- EWTX Nasdaq
- Market Cap
- MYGN 2.0B
- EWTX 2.7B
- IPO Year
- MYGN 1995
- EWTX 2021
- Fundamental
- Price
- MYGN $13.36
- EWTX $30.78
- Analyst Decision
- MYGN Hold
- EWTX Buy
- Analyst Count
- MYGN 12
- EWTX 6
- Target Price
- MYGN $23.92
- EWTX $44.83
- AVG Volume (30 Days)
- MYGN 942.4K
- EWTX 865.8K
- Earning Date
- MYGN 11-07-2024
- EWTX 02-20-2025
- Dividend Yield
- MYGN N/A
- EWTX N/A
- EPS Growth
- MYGN N/A
- EWTX N/A
- EPS
- MYGN N/A
- EWTX N/A
- Revenue
- MYGN $823,600,000.00
- EWTX N/A
- Revenue This Year
- MYGN $13.82
- EWTX N/A
- Revenue Next Year
- MYGN $4.59
- EWTX N/A
- P/E Ratio
- MYGN N/A
- EWTX N/A
- Revenue Growth
- MYGN 12.15
- EWTX N/A
- 52 Week Low
- MYGN $12.87
- EWTX $9.00
- 52 Week High
- MYGN $29.30
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- EWTX 48.57
- Support Level
- MYGN $12.87
- EWTX $29.39
- Resistance Level
- MYGN $15.44
- EWTX $35.50
- Average True Range (ATR)
- MYGN 0.84
- EWTX 2.42
- MACD
- MYGN -0.02
- EWTX 0.02
- Stochastic Oscillator
- MYGN 12.37
- EWTX 44.47
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.